Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2016

Open Access 01-12-2016 | Review

Aberrant splicing and drug resistance in AML

Authors: Rosalia de Necochea-Campion, Geoffrey P. Shouse, Qi Zhou, Saied Mirshahidi, Chien-Shing Chen

Published in: Journal of Hematology & Oncology | Issue 1/2016

Login to get access

Abstract

The advent of next-generation sequencing technologies has unveiled a new window into the heterogeneity of acute myeloid leukemia (AML). In particular, recurrent mutations in spliceosome machinery and genome-wide aberrant splicing events have been recognized as a prominent component of this disease. This review will focus on how these factors influence drug resistance through altered splicing of tumor suppressor and oncogenes and dysregulation of the apoptotic signaling network. A better understanding of these factors in disease progression is necessary to design appropriate therapeutic strategies recognizing specific alternatively spliced or mutated oncogenic targets.
Literature
1.
2.
Dohner H, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453–74.CrossRefPubMed
3.
4.
5.
Hahn CN, et al. Splice factor mutations and alternative splicing as drivers of hematopoietic malignancy. Immunol Rev. 2015;263(1):257–78.CrossRefPubMed
6.
7.
Zhang J, Manley JL. Misregulation of pre-mRNA alternative splicing in cancer. Cancer Discov. 2013;3(11):1228–37.CrossRefPubMed
8.
Grech G, et al. Expression of different functional isoforms in haematopoiesis. Int J Hematol. 2014;99(1):4–11.CrossRefPubMed
9.
Larsson CA, Cote G, Quintas-Cardama A. The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome. Mol Cancer Res. 2013;11(8):815–27.CrossRefPubMedPubMedCentral
10.
Boultwood J, et al. The role of splicing factor mutations in the pathogenesis of the myelodysplastic syndromes. Adv Biol Regul. 2014;54:153–61.CrossRefPubMed
11.
12.
Malcovati L, et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood. 2011;118(24):6239–46.CrossRefPubMedPubMedCentral
13.
Thol F, et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood. 2012;119(15):3578–84.CrossRefPubMed
14.
15.
Dolatshad H, et al. Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells. Leukemia. 2015;29(8):1798.CrossRefPubMed
16.
17.
Komeno Y, et al. SRSF2 is essential for hematopoiesis, and its myelodysplastic syndrome-related mutations dysregulate alternative pre-mRNA splicing. Mol Cell Biol. 2015;35(17):3071–82.CrossRefPubMedPubMedCentral
18.
Yoshida K, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478(7367):64–9.CrossRefPubMed
19.
Karimi M, et al. High-throughput mutational screening adds clinically important information in myelodysplastic syndromes and secondary or therapy-related acute myeloid leukemia. Haematologica. 2015;100(6):e223–5.CrossRefPubMedPubMedCentral
20.
Ohgami RS, et al. Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations. Mod Pathol. 2015;28(5):706–14.CrossRefPubMed
21.
Adamia S, et al. A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets. Clin Cancer Res. 2014;20(5):1135–45.CrossRefPubMed
22.
Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene. 2006;25(34):4798–811.CrossRefPubMed
23.
Tait SW, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol. 2010;11(9):621–32.CrossRefPubMed
24.
25.
Ishizawa J, et al. Mitochondrial profiling of acute myeloid leukemia in the assessment of response to apoptosis modulating drugs. PLoS One. 2015;10(9):e0138377.CrossRefPubMedPubMedCentral
26.
27.
Dubrez L, Berthelet J, Glorian V. IAP proteins as targets for drug development in oncology. Onco Targets Ther. 2013;9:1285–304.CrossRefPubMed
28.
Anczukow O, et al. The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation. Nat Struct Mol Biol. 2012;19(2):220–8.CrossRefPubMedPubMedCentral
29.
30.
31.
32.
Wang Y, et al. The splicing factor RBM4 controls apoptosis, proliferation, and migration to suppress tumor progression. Cancer Cell. 2014;26(3):374–89.CrossRefPubMedPubMedCentral
33.
34.
Adamia S, et al. NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML. Blood. 2014;123(18):2816–25.CrossRefPubMedPubMedCentral
35.
Zhou J, et al. Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. Blood. 2009;113(17):4052–62.CrossRefPubMed
36.
Obiol-Pardo C, Granadino-Roldan JM, Rubio-Martinez J. Protein-protein recognition as a first step towards the inhibition of XIAP and survivin anti-apoptotic proteins. J Mol Recognit. 2008;21(3):190–204.CrossRefPubMed
37.
38.
39.
Ceballos-Cancino G, et al. Regulation of mitochondrial Smac/DIABLO-selective release by survivin. Oncogene. 2007;26(54):7569–75.CrossRefPubMed
40.
Moore AS, et al. BIRC5 (survivin) splice variant expression correlates with refractory disease and poor outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2014;61(4):647–52.CrossRefPubMed
41.
Wagner M, et al. In vivo expression of survivin and its splice variant survivin-2B: impact on clinical outcome in acute myeloid leukemia. Int J Cancer. 2006;119(6):1291–7.CrossRefPubMed
42.
Shultz JC, et al. Alternative splicing of caspase 9 is modulated by the phosphoinositide 3-kinase/Akt pathway via phosphorylation of SRp30a. Cancer Res. 2010;70(22):9185–96.CrossRefPubMedPubMedCentral
43.
44.
de Necochea-Campion R, et al. AML sensitivity to YM155 is modulated through AKT and Mcl-1. Cancer Lett. 2015;366(1):44–51.CrossRefPubMed
45.
46.
Nishida S, et al. AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1. Blood. 2006;107(8):3303–12.CrossRefPubMed
47.
Mint Mohamed A, et al. Oncogene- and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML). Oncotarget. 2016;7(3):2889-909.
48.
Andersson C, et al. Reduction in WT1 gene expression during early treatment predicts the outcome in patients with acute myeloid leukemia. Diagn Mol Pathol. 2012;21(4):225–33.CrossRefPubMed
49.
Korotayev K, Ginsberg D. Many pathways to apoptosis: E2F1 regulates splicing of apoptotic genes. Cell Death Differ. 2008;15(12):1813–4.CrossRefPubMed
50.
Merdzhanova G, et al. E2F1 controls alternative splicing pattern of genes involved in apoptosis through upregulation of the splicing factor SC35. Cell Death Differ. 2008;15(12):1815–23.CrossRefPubMed
51.
Engelmann D, Putzer BM. The dark side of E2F1: in transit beyond apoptosis. Cancer Res. 2012;72(3):571–5.CrossRefPubMed
52.
Stoleriu MG, et al. A new strategy in the treatment of chemoresistant lung adenocarcinoma via specific siRNA transfection of SRF, E2F1, survivin, HIF and STAT3. Eur J Cardiothorac Surg. 2014;46(5):877–86.CrossRefPubMed
53.
54.
Perry 3rd WL, et al. Human splicing factor SPF45 (RBM17) confers broad multidrug resistance to anticancer drugs when overexpressed—a phenotype partially reversed by selective estrogen receptor modulators. Cancer Res. 2005;65(15):6593–600.CrossRefPubMed
55.
Tejedor JR, Papasaikas P, Valcarcel J. Genome-wide identification of Fas/CD95 alternative splicing regulators reveals links with iron homeostasis. Mol Cell. 2015;57(1):23–38.CrossRefPubMed
56.
Aratake K, et al. A cross-talk between RNA splicing and signaling pathway alters Fas gene expression at post-transcriptional level: alternative splicing of Fas mRNA in the leukemic U937 cells. J Lab Clin Med. 2005;146(3):184–91.CrossRefPubMed
57.
Inaba H, et al. mRNA expression of variant Fas molecules in acute leukemia cells. Am J Hematol. 1999;62(3):150–8.CrossRefPubMed
58.
Himeji D, et al. Characterization of caspase-8L: a novel isoform of caspase-8 that behaves as an inhibitor of the caspase cascade. Blood. 2002;99(11):4070–8.CrossRefPubMed
59.
Mohr A, et al. Caspase-8L expression protects CD34+ hematopoietic progenitor cells and leukemic cells from CD95-mediated apoptosis. Oncogene. 2005;24(14):2421–9.CrossRefPubMed
60.
Stasi R, et al. Analysis of treatment failure in patients with minimally differentiated acute myeloid leukemia (AML-M0). Blood. 1994;83(6):1619–25.PubMed
61.
Schmohl JU, et al. Death receptor expression on blasts in AML is associated with unfavorable prognosis. Anticancer Res. 2015;35(7):4043–52.PubMed
62.
Prabhakar BS, Mulherkar N, Prasad KV. Role of IG20 splice variants in TRAIL resistance. Clin Cancer Res. 2008;14(2):347–51.CrossRefPubMed
63.
Lim KM, Yeo WS, Chow VT. Antisense abrogation of DENN expression induces apoptosis of leukemia cells in vitro, causes tumor regression in vivo and alters the transcription of genes involved in apoptosis and the cell cycle. Int J Cancer. 2004;109(1):24–37.CrossRefPubMed
64.
65.
Krueger A, et al. Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J Biol Chem. 2001;276(23):20633–40.CrossRefPubMed
66.
Safa AR, Pollok KE. Targeting the anti-apoptotic protein c-FLIP for cancer therapy. Cancers (Basel). 2011;3(2):1639–71.CrossRef
67.
McLornan D, et al. Prognostic and therapeutic relevance of c-FLIP in acute myeloid leukaemia. Br J Haematol. 2013;160(2):188–98.CrossRefPubMed
68.
Akgul C, Moulding DA, Edwards SW. Alternative splicing of Bcl-2-related genes: functional consequences and potential therapeutic applications. Cell Mol Life Sci. 2004;61(17):2189–99.CrossRefPubMed
69.
Renshaw SA, et al. Three novel Bid proteins generated by alternative splicing of the human Bid gene. J Biol Chem. 2004;279(4):2846–55.CrossRefPubMed
70.
71.
Goncharenko-Khaider N, et al. The inhibition of Bid expression by Akt leads to resistance to TRAIL-induced apoptosis in ovarian cancer cells. Oncogene. 2010;29(40):5523–36.CrossRefPubMedPubMedCentral
72.
73.
74.
75.
Marani M, et al. Identification of novel isoforms of the BH3 domain protein Bim which directly activate Bax to trigger apoptosis. Mol Cell Biol. 2002;22(11):3577–89.CrossRefPubMedPubMedCentral
76.
Weber A, et al. BimS-induced apoptosis requires mitochondrial localization but not interaction with anti-apoptotic Bcl-2 proteins. J Cell Biol. 2007;177(4):625–36.CrossRefPubMedPubMedCentral
77.
Abrams MT, et al. Inhibition of glucocorticoid-induced apoptosis by targeting the major splice variants of BIM mRNA with small interfering RNA and short hairpin RNA. J Biol Chem. 2004;279(53):55809–17.CrossRefPubMed
78.
Ng KP, et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med. 2012;18(4):521–8.CrossRefPubMed
79.
Wang Z, Sun Y. Identification and characterization of two splicing variants of human Noxa. Anticancer Res. 2008;28(3A):1667–74.PubMed
80.
Fu J, Jin Y, Arend LJ. Smac3, a novel Smac/DIABLO splicing variant, attenuates the stability and apoptosis-inhibiting activity of X-linked inhibitor of apoptosis protein. J Biol Chem. 2003;278(52):52660–72.CrossRefPubMed
81.
Ju WC, et al. X-linked inhibitor of apoptosis-associated factor l (XAFl) enhances the sensitivity of colorectal cancer cells to cisplatin. Med Oncol. 2014;31(12):273.CrossRefPubMed
82.
Kim KS, et al. Enhancement of cellular radiation sensitivity through degradation of Chk1 by the XIAP-XAF1 complex. Cancer Biol Ther. 2014;15(12):1622–34.CrossRefPubMedPubMedCentral
83.
Hatakeyama K, et al. A novel splice variant of XIAP-associated factor 1 (XAF1) is expressed in peripheral blood containing gastric cancer-derived circulating tumor cells. Gastric Cancer. 2015;18(4):751–61.CrossRefPubMed
84.
Tse MK, et al. Domain organization of XAF1 and the identification and characterization of XIAP(RING)-binding domain of XAF1. Protein Sci. 2012;21(10):1418–28.CrossRefPubMedPubMedCentral
85.
Notarbartolo M, et al. NAIP-deltaEx10-11: a novel splice variant of the apoptosis inhibitor NAIP differently expressed in drug-sensitive and multidrug-resistant HL60 leukemia cells. Leuk Res. 2002;26(9):857–62.CrossRefPubMed
86.
Huang TS, et al. LEDGF/p75 has increased expression in blasts from chemotherapy-resistant human acute myelogenic leukemia patients and protects leukemia cells from apoptosis in vitro. Mol Cancer. 2007;6:31.CrossRefPubMedPubMedCentral
87.
Brown-Bryan TA, et al. Alternative splicing and caspase-mediated cleavage generate antagonistic variants of the stress oncoprotein LEDGF/p75. Mol Cancer Res. 2008;6(8):1293–307.CrossRefPubMedPubMedCentral
88.
Bonnal S, Vigevani L, Valcarcel J. The spliceosome as a target of novel antitumour drugs. Nat Rev Drug Discov. 2012;11(11):847–59.CrossRefPubMed
89.
Gao Y, et al. Comparison of splicing factor 3b inhibitors in human cells. Chembiochem. 2013;14(1):49–52.CrossRefPubMed
90.
Wojtuszkiewicz A, et al. Spliceosome inhibitor meayamycin B as a novel potential chemotherapeutic agent in ALL and AML. Blood. 2014;124(21):924.
91.
Webb TR, Joyner AS, Potter PM. The development and application of small molecule modulators of SF3b as therapeutic agents for cancer. Drug Discov Today. 2013;18(1-2):43–9.CrossRefPubMed
92.
93.
Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136–52.CrossRefPubMed
94.
95.
Metadata
Title
Aberrant splicing and drug resistance in AML
Authors
Rosalia de Necochea-Campion
Geoffrey P. Shouse
Qi Zhou
Saied Mirshahidi
Chien-Shing Chen
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2016
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-016-0315-9

Other articles of this Issue 1/2016

Journal of Hematology & Oncology 1/2016 Go to the issue

Research

Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors

Rapid communication

Minimal residual disease- and graft-vs.-host disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant

Review

Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma

Review

CCR9 in cancer: oncogenic role and therapeutic targeting

Research

Modification of platinum sensitivity by KEAP1/NRF2 signals in non-small cell lung cancer

Research

A positive feedback loop involving the Wnt/β-catenin/MYC/Sox2 axis defines a highly tumorigenic cell subpopulation in ALK-positive anaplastic large cell lymphoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits